Auxly Cannabis Group Inc (TSE:XLY)
TSX:XLY
Top Page
Auxly Cannabis Group
(TSX:XLY)
Select Model
Select Model
Rating:67Neutral
Price Target:
C$0.14
▲(0.71% Upside)
Action:ReiteratedDate:01/04/26
The score is driven by improved financial performance and a low P/E, signaling a meaningful TTM profitability turnaround and discounted valuation. These positives are tempered by weak technical momentum and elevated consistency risk from historically volatile earnings and less robust cash conversion.
Positive Factors
Profitability turnaround
TTM margins near 60% gross and ~30% operating/net demonstrate substantial operational leverage and a meaningful profitability inflection. Sustained margins can generate durable cash flow, fund reinvestment or debt reduction, and provide a structural advantage versus lower-margin peers.
Negative Factors
Multi-year earnings volatility
A history of deep losses across 2021–2023 and a loss in 2024 demonstrates execution and cyclicality risks. This uneven record undermines confidence that current profitability will persist, raising uncertainty about the sustainability of returns and planning for longer-term investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability turnaround
TTM margins near 60% gross and ~30% operating/net demonstrate substantial operational leverage and a meaningful profitability inflection. Sustained margins can generate durable cash flow, fund reinvestment or debt reduction, and provide a structural advantage versus lower-margin peers.
Read all positive factors
Auxly Cannabis Group (XLY) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$177.72M
Dividend YieldN/A
Average Volume (3M)979.68K
Price to Earnings (P/E)2.4
Beta (1Y)1.37
Revenue Growth27.38%
EPS GrowthN/A
CountryCA
Employees388
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,367,038,800
10 Day Avg. Volume1,296,089
30 Day Avg. Volume979,678
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.42
Price to Sales (P/S)0.39
P/FCF Ratio3.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)C$163.90M
Auxly Cannabis Group Business Overview & Revenue Model
Company Description
Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. It off...
How the Company Makes Money
Auxly Cannabis Group generates revenue primarily through the sale of cannabis products to both wholesale and retail markets. The company has established a revenue model that includes multiple key streams: direct sales of cannabis products through ...
Auxly Cannabis Group Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 146.00M | 122.33M | 101.08M | 94.47M | 83.83M | 50.80M |
| Gross Profit | 86.93M | 59.93M | 21.28M | 17.92M | 19.29M | 11.14M |
| EBITDA | 53.87M | 24.38M | -10.89M | -93.40M | -13.64M | -57.18M |
| Net Income | 45.34M | -16.35M | -44.51M | -130.29M | -45.91M | -87.43M |
Balance Sheet | ||||||
| Total Assets | 276.43M | 261.53M | 261.90M | 331.82M | 450.42M | 378.96M |
| Cash, Cash Equivalents and Short-Term Investments | 30.62M | 18.50M | 15.75M | 14.78M | 14.89M | 21.50M |
| Total Debt | 65.99M | 68.47M | 159.04M | 193.59M | 190.10M | 124.68M |
| Total Liabilities | 103.91M | 145.87M | 210.86M | 246.13M | 242.31M | 187.43M |
| Stockholders Equity | 172.52M | 115.66M | 51.05M | 90.41M | 212.52M | 195.94M |
Cash Flow | ||||||
| Free Cash Flow | 15.86M | 14.02M | 6.61M | -11.67M | -50.01M | -53.86M |
| Operating Cash Flow | 18.57M | 16.78M | 8.21M | -2.48M | -49.63M | -33.13M |
| Investing Cash Flow | -2.60M | -445.00K | -1.56M | 1.18M | 17.33M | -14.53M |
| Financing Cash Flow | -4.44M | -13.59M | -5.68M | 1.18M | 26.40M | 24.74M |
Auxly Cannabis Group Technical Analysis
Negative
0.14
Price Trends
0.13
Positive
0.14
Negative
0.14
Negative
Market Momentum
<0.01
Negative
51.19
Neutral
83.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:XLY, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.13, and above the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.19 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:XLY.
Auxly Cannabis Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | C$177.72M | 2.37 | 32.74% | ― | 27.38% | ― | |
61 Neutral | C$1.33B | -104.58 | -0.87% | ― | 22.20% | ― | |
56 Neutral | C$1.52B | -13.95 | -9.71% | ― | 4.27% | 3.41% | |
54 Neutral | C$248.13M | 3.90 | 4.86% | ― | 62.15% | 60.50% | |
52 Neutral | C$262.00M | 44.94 | -7.78% | ― | 23.87% | -19.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$512.43M | -2.15 | -52.88% | ― | -0.67% | 58.98% |
* Healthcare Sector Average
TSE:XLY
Auxly Cannabis Group
0.13
0.05
52.94%
TSE:WEED
Canopy Growth
1.28
-0.23
-15.23%
TSE:OGI
Organigram Global
1.82
0.29
18.95%
TSE:ACB
Aurora Cannabis
4.62
-1.98
-30.00%
TSE:CRON
Cronos Group
3.51
0.90
34.48%
TSE:TRUL
Trulieve Cannabis
7.91
2.38
43.04%
Auxly Cannabis Group Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Auxly Caps Strong 2025 With New Product Wins and Sets 2026 Growth Plan
Positive
Jan 8, 2026
Auxly reported that 2025 was a strong year marked by market share gains, with the company ranking as the third-largest licensed producer in Canada and its Back Forty label holding the top cannabis brand position nationwide. Key innovations include...
Business Operations and StrategyFinancial Disclosures
Auxly Cannabis Group Reports Robust Q3 2025 Financial Results
Positive
Nov 13, 2025
Auxly Cannabis Group reported a strong financial performance for the third quarter of 2025, with net revenues increasing by 20% to $39.9 million and a significant rise in net income by 533% to $20.5 million. The company’s strategic focus on ...
Financial Disclosures
Auxly Cannabis Group to Announce Q3 2025 Financial Results
Neutral
Nov 6, 2025
Auxly Cannabis Group Inc. has announced that it will release its financial results for the third quarter of 2025 on November 13, before the markets open. This announcement is significant as it provides stakeholders with insights into the company&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.